Cerecor Inc. (CERC): Price and Financial Metrics

Cerecor Inc. (CERC): $2.93

-0.05 (-1.68%)

POWR Rating

Component Grades













Add CERC to Watchlist
Sign Up

Industry: Biotech



in industry

CERC Stock Price Chart Interactive Chart >

Price chart for CERC

CERC Price/Volume Stats

Current price $2.93 52-week high $4.50
Prev. close $2.98 52-week low $1.98
Day low $2.90 Volume 268,000
Day high $2.98 Avg. volume 1,265,434
50-day MA $3.05 Dividend yield N/A
200-day MA $2.95 Market Cap 281.31M

Cerecor Inc. (CERC) Company Bio

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

CERC Latest News Stream

Event/Time News Detail
Loading, please wait...

CERC Latest Social Stream

Loading social stream, please wait...

View Full CERC Social Stream

Latest CERC News From Around the Web

Below are the latest news stories about Cerecor Inc that investors may wish to consider to help them evaluate CERC as an investment opportunity.

Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

Name change underscores the Company’s transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates advancing in development with eight ongoing clinical programsFour therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approvalMultiple data readouts anticipated in the second half of 2021 WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWS

Yahoo | August 26, 2021

Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsAnnounced plans to explore CERC-002 in patients with moderate-to-severe ulcerative colitis refractory to anti-TNF alpha therapiesCompleted $35 million debt financing that extends cash runway and supports multiple clinical catalysts anticipated in the second half of 2021 ROCKVIL

Yahoo | August 2, 2021

Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn’s Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatmentsROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare gen

Yahoo | August 2, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning!

William White on InvestorPlace | July 28, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Greetings, trader!

William White on InvestorPlace | July 27, 2021

Read More 'CERC' Stories Here

CERC Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -32.49%
5-year -17.93%
2022 N/A
2021 0.00%
2020 -51.02%
2019 66.87%
2018 0.94%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7041 seconds.